Security key
M96088105
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN)
CUSIP: M96088105
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Ordinary Shares, par value NIS 0.01 per share
- Shares outstanding
- 48,684,257
- Total 13F shares
- 39,798,464
- Share change
- -1,934,777
- Total reported value
- $545,161,051
- Put/Call ratio
- 35%
- Price per share
- $13.70
- Number of holders
- 149
- Value change
- +$3,475,596
- Number of buys
- 82
- Number of sells
- 70
Report period
Q2 2025
Institutions
149
Top holders
10
URGN full security history
Newer quarter: Q3 2025
Previous quarter: Q1 2025
UroGen Pharma Ltd. SEC filings
UroGen Pharma Ltd. company facts
Broader feeds
Reporting periods
Holder history for CUSIP M96088105
Recent filing periods:
Top shareholders of URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| MORGAN STANLEY |
13D/G
13F
|
Company |
5.4%
|
2,488,299
|
$35,433,378 | +$24,712,637 | 30 Jun 2025 | |
| MENORA MIVTACHIM HOLDINGS LTD. |
13F
13D/G
|
Company |
5%
from 13D/G
|
2,303,031
|
$25,471,523 | — | 31 Mar 2025 | |
| Soleus Capital Master Fund, L.P. |
13D/G
|
— |
4.7%
|
2,185,000
|
$31,114,400 | -$1,993,600 | 30 Jun 2025 | |
| Adage Capital Management, L.P. |
13D/G
|
— |
2.8%
|
1,277,000
|
$13,740,520 | -$17,765,685 | 31 Mar 2025 | |
| Monograph Capital Holdings Advisors, LLC |
13D/G
|
Monograph Capital Partners I, L.P. |
1.8%
|
838,615
|
$8,503,556 | $0 | 05 Jun 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
9%
|
4,360,524
|
$48,227,395 | — | 31 Mar 2025 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
7.9%
|
3,834,794
|
$42,412,822 | — | 31 Mar 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
6.6%
|
3,206,271
|
$35,461,357 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
5%
|
2,423,463
|
$26,803,500 | — | 31 Mar 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
4.4%
|
2,152,957
|
$23,811,704 | — | 31 Mar 2025 | |
| TORONTO DOMINION BANK |
13F
|
Company |
3.6%
|
1,749,142
|
$19,345,510 | — | 31 Mar 2025 | |
| ACORN CAPITAL ADVISORS, LLC |
13F
|
Company |
3.1%
|
1,516,303
|
$16,770,311 | — | 31 Mar 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.8%
|
1,381,158
|
$15,275,607 | — | 31 Mar 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
2.8%
|
1,363,399
|
$15,079,193 | — | 31 Mar 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
2.6%
|
1,277,000
|
$14,123,620 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
2.4%
|
1,173,088
|
$12,974,353 | — | 31 Mar 2025 | |
| Rosalind Advisors, Inc. |
13F
|
Company |
2%
|
950,000
|
$10,507,000 | — | 31 Mar 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
1.7%
|
815,000
|
$9,013,900 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.6%
|
795,012
|
$8,792,833 | — | 31 Mar 2025 | |
| Migdal Insurance & Financial Holdings Ltd. |
13F
|
Company |
1.6%
|
786,472
|
$8,698,000 | — | 31 Mar 2025 | |
| Wildcat Capital Management, LLC |
13F
|
Company |
1%
|
495,606
|
$5,481,402 | — | 31 Mar 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
1%
|
492,515
|
$5,447,216 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.97%
|
473,330
|
$5,235,029 | — | 31 Mar 2025 | |
| SUPERSTRING CAPITAL MANAGEMENT LP |
13F
|
Company |
0.87%
|
423,632
|
$4,685,370 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.87%
|
423,585
|
$4,684,850 | — | 31 Mar 2025 | |
| Hudson Bay Capital Management LP |
13F
|
Company |
0.84%
|
410,607
|
$4,541,313 | — | 31 Mar 2025 | |
| Atom Investors LP |
13F
|
Company |
0.82%
|
400,560
|
$4,430,194 | — | 31 Mar 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.81%
|
393,153
|
$4,348,272 | — | 31 Mar 2025 | |
| Harel Insurance Investments & Financial Services Ltd. |
13F
|
Company |
0.77%
|
373,982
|
$4,136,000 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.76%
|
370,959
|
$4,102,806 | — | 31 Mar 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.76%
|
368,654
|
$4,079,000 | — | 31 Mar 2025 | |
| Stonepine Capital Management, LLC |
13F
|
Company |
0.68%
|
333,400
|
$3,687,404 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.63%
|
306,371
|
$3,388,463 | — | 31 Mar 2025 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
0.62%
|
303,397
|
$3,398,046 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.59%
|
285,614
|
$3,158,891 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.58%
|
284,334
|
$3,144,734 | — | 31 Mar 2025 | |
| RICE HALL JAMES & ASSOCIATES, LLC |
13F
|
Company |
0.53%
|
255,791
|
$2,829,048 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.51%
|
250,429
|
$2,769,744 | — | 31 Mar 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.48%
|
236,006
|
$2,610,221 | — | 31 Mar 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.44%
|
216,478
|
$2,394,246 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.4%
|
196,802
|
$2,176,630 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.39%
|
189,677
|
$2,097,828 | — | 31 Mar 2025 | |
| ARK Investment Management LLC |
13F
|
Company |
0.38%
|
185,790
|
$2,054,837 | — | 31 Mar 2025 | |
| SG Americas Securities, LLC |
13F
|
Company |
0.33%
|
162,514
|
$1,797,000 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.3%
|
148,078
|
$1,637,743 | — | 31 Mar 2025 | |
| Epoch Investment Partners, Inc. |
13F
|
Company |
0.27%
|
132,439
|
$1,464,775 | — | 31 Mar 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.23%
|
114,066
|
$1,261,569 | — | 31 Mar 2025 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.22%
|
107,622
|
$1,190,299 | — | 31 Mar 2025 | |
| CANTOR FITZGERALD, L. P. |
13F
|
Individual |
0.2%
|
95,000
|
$1,050,700 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.19%
|
93,547
|
$1,034,630 | — | 31 Mar 2025 |
Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q2 2025
As of 30 Jun 2025,
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) was held by
149 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
39,798,464 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, TORONTO DOMINION BANK, MORGAN STANLEY, BlackRock, Inc., Jefferies Financial Group Inc., Soleus Capital Management, L.P., SILVERARC CAPITAL MANAGEMENT, LLC, ACORN CAPITAL ADVISORS, LLC, MENORA MIVTACHIM HOLDINGS LTD., and SG Americas Securities, LLC.
This page lists
150
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
139
Q2 2025 holders
149
Holder diff
10
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.